Kristina Burow - Jun 6, 2023 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
Director
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Stock symbol
BEAM
Transactions as of
Jun 6, 2023
Transactions value $
$0
Form type
4
Date filed
6/8/2023, 05:02 PM
Previous filing
Sep 2, 2022
Next filing
Jun 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BEAM Common Stock 2.72M Jun 6, 2023 See footnote F1, F2
holding BEAM Common Stock 2.72M Jun 6, 2023 See footnote F1, F3
holding BEAM Common Stock 26K Jun 6, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Award $0 +16.5K $0.00 16.5K Jun 6, 2023 Common Stock 16.5K $34.33 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person as a result of a distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2 The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The reporting person has an interest in the GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH IX. The reporting person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
F3 The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. The reporting person has an interest in the Overage GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH Overage. The reporting person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
F4 The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.